Potential association between tafamidis and aortic stenosis progression in cardiac amyloidosis

29 August 2025 (12:15 - 13:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Ronak Patel

(United States of America)

4 More presentations in this session

Presentation thumbnail

Clinical characteristics and outcomes of left ventricular hypertrophy in severe primary mitral regurgitation

Mr H. Wong (Singapore, SG)

Abstract Slides Video

Presentation thumbnail

Left ventricular myocardial work in degenerative mitral regurgitation and its impact on outcome

Doctor P. Turgeon (Quebec, CA)

Abstract Slides Video

Presentation thumbnail

Short-term left ventricular systolic dysfunction and long-term outcome in postsurgical patients with primary mitral regurgitation

Doctor X. Zhang (Chengdu, CN)

Abstract Slides Video

Presentation thumbnail

Work the stage: myocardial work and aortic valve stenosis cardiac damage staging independently predict all-cause mortality in patients undergoing transcatheter aortic valve replacement

Doctor Z. Ladanyi (Budapest, HU)

Abstract Slides Video

Access the full session

Session thumbnail

Degenerative left valve disease and left ventricle

The Event

Event poster

ESC Congress 2025

29 August 2025 12:15 CET

You may be interested in

Congress Presentation

Prevalence and prognostic impact of aortic stenosis in wild-type transthyretin cardiac amyloidosis

Congress Presentation

Prognostic significance of concomitant transthyretin cardiac amyloidosis and severe aortic stenosis: insights from a systematic review and meta-analysis

Congress Presentation

Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources